RxDoctor Payments Data

Joseph Fero, NP

Nurse Practitioner · Vancleave, MSNPI 1669457925

Payments from drug & device makers

$827in general payments, 2019–2025

Across 18 payments — averaging $45.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$271
  • Johnson & Johnson$134
  • GSK$119
  • Amgen$119
  • Idorsia Pharmaceuticals US Inc$92
  • AbbVie$66
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 70th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$16,820
Medicare patients
109
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$30,050
MounjaroTirzepatide22$25,271
EliquisApixaban31$17,946
TrulicityDulaglutide18$17,125
JardianceEmpagliflozin22$14,141
Combivent RespimatIpratropium/Albuterol Sulfate19$13,915
OzempicSemaglutide12$13,502
FarxigaDapagliflozin Propanediol15$13,171
LinzessLinaclotide13$12,275
SymbicortBudesonide/Formoterol Fumarate28$9,539
Fiasp FlextouchInsulin Aspart (Niacinamide)17$8,955
Tresiba Flextouch U-100Insulin Degludec18$4,359
Albuterol Sulfate HfaAlbuterol Sulfate100$3,919
Celecoxib52$2,759
Tizanidine Hcl105$1,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$119$30,05045 claims
AstraZenecaFarxiga, Symbicort$271$22,71043 claims
AbbVieLinzess$66$12,27513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Vancleave

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →